Compare Danaher Corporation (DHR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Danaher Corporation trades at $217.88 (market cap $152.87B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Danaher Corporation is far larger — about 2× Regeneron Pharmaceuticals Inc's market cap, and Danaher Corporation pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DHR | REGN | |
|---|---|---|
Market Cap | $152.87B | $76.14B |
Volume | 5,228,698 | 500,239 |
Sector | Health | Health |
52-Week High | $242.05 | $852.03 |
52-Week Low | $161.91 | $557.73 |
Typical Hold Time | 69 Days | 107 Days |
Enterprise Value | $175.08B | $70.85B |
Dividend Yield | 0.74% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
